Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

Table 1

Clinical characteristics of 45 liver cirrhosis patients with HCC.

Dose of sorafenib	200 mg	400 mg	800 mg
No. of patients	11	27	7
Mean age	72.1 ± 7	69.4 ± 6	66.1 ± 7
Gender (M/F)	7/4	24/3	7/0
Type of cirrhosis; (HBV/HCV/non B non C)	1/8/2	5/17/5	2/1/4
Child-Pugh classification; (A/B/C)	8/3/0	26/1/0	5/2/0
Stage; (III/IVAIIVB)	0/9/2	1/24/2	0/7/0
JIS score; (2/3/4/5)	0/8/3/0	0/26/1/0	0/5/2/0